Skip to content
DataLookout
Menu

NCT07946913

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
Timeframe: Week 12

Secondary (8)

Change from baseline in UAS7 at each assessment visit (excluding Week 12)
The proportion of participants with UAS7 = 0 at each assessment visit
The proportion of participants with UAS7 ≤ 6at each assessment visit
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
Show 3 moreShow less
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
The incidence of adverse events during the study

Arms and interventions

LP-003 groupExperimental

Participants received LP-003 subcutaneously during the 48-week treatment period

Omalizumab groupActive comparator

Participants received omalizumab subcutaneously during the 48-week treatment period

Biologicals: LP-003 Injection, Omalizumab

Sites

2 sites in 1 country